This is a working overview of lipolysis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-19. Anything still debated is marked as such rather than presented as settled.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Specifically, it binds to microtubule-associated proteins and/or to tubulin and produces depolymerization of microtubules (Kd = 10–20 μM for estramustine), resulting in the arrest of cell division in the G2/M phase (specifically metaphase). EMP was originally thought to mediate its cytostatic effects as a prodrug of normustine, a nitrogen mustard, and hence was thought to be an alkylating antineoplastic agent. However, subsequent research has found that EMP is devoid of alkylating actions, and that the influence of EMP on microtubules is mediated by intact estramustine and estromustine, with normustine or estradiol alone having only minor or negligible effects. As such, the unique properties of the estramustine and estromustine structures, containing a carbamate-ester bond, appear to be responsible for the cytostatic effects of EMP. In addition to its antimitotic actions, EMP has also been found to produce other cytostatic effects, including induction of apoptosis, interference with DNA synthesis, nuclear matrix interaction, cell membrane alterations, induction of reactive oxygen species (free oxygen radicals), and possibly additional mechanisms. EMP has been found to have a radiosensitizing effect in prostate cancer and glioma cells, improving sensitivity to radiation therapy as well. The cytostatic metabolites of EMP are accumulated in tissues in a selective manner, for instance in prostate cancer cells.
Extreme exercise can make capillaries vulnerable, with a breaking point similar to that of collagen. Capillary permeability can be increased by the release of certain cytokines, anaphylatoxins, or other mediators (such as leukotrienes, prostaglandins, histamine, bradykinin, etc.) highly influenced by the immune system.
One application of thermal ionization is thermal ionization mass spectrometry (TIMS). In thermal ionization mass spectrometry, a chemically purified material is placed onto a filament which is then heated to high temperatures to cause some of the material to be ionized as it is thermally desorbed (boiled off) the hot filament. Filaments are generally flat pieces of metal around 1–2 mm (0.039–0.079 in) wide, 0.1 mm (0.0039 in) thick, bent into an upside-down U shape and attached to two contacts that supply a current. This method is widely used in radiometric dating, where the sample is ionized under vacuum. The ions being produced at the filament are focused into an ion beam and then passed through a magnetic field to separate them by mass. The relative abundances of different isotopes can then be measured, yielding isotope ratios. When these isotope ratios are measured by TIMS, mass-dependent fractionation occurs as species are emitted by the hot filament. Fractionation occurs due to the excitation of the sample and therefore must be corrected for accurate measurement of the isotope ratio. There are several advantages of the TIMS method. It has a simple design, is less expensive than other mass spectrometers, and produces stable ion emissions. It requires a stable power supply, and is suitable for species with a low ionization energy, such as strontium and lead. The disadvantages of this method stem from the maximum temperature achieved in thermal ionization.
In the course of the 1960s and 1970s, Cold War participants struggled to adjust to a new, more complicated pattern of international relations in which the world was no longer divided into two clearly opposed blocs. From the beginning of the post-war period with American help, Western Europe and Japan rapidly recovered from the destruction of World War II and sustained strong economic growth throughout the 1950s and 1960s, with per capita GDPs approaching those of the United States, while Eastern Bloc economies stagnated.
== Definition of recession == A recession is a period of two quarters of negative GDP growth. The countries listed are those that officially announced that they were in recession. It is worth noting that some developed countries such as South Korea and Australia did not enter recession (indeed Australia contracted for the last quarter of 2008 only to grow 1% for the first half of 2009). Poland, then considered to be an emerging market country, also avoided the recession as a result of their strong domestic market, low private debt and flexible currency.
Sources: en.wikipedia.org
== Current use == Obsidian can be used to make extremely sharp knives, and obsidian blades are a type of glass knife made using naturally occurring obsidian instead of manufactured glass. Obsidian is used by some surgeons for scalpel blades, although this is not approved by the US Food and Drug Administration (FDA) for use on humans. Well-crafted obsidian blades, like any glass knife, can have a cutting edge many times sharper than high-quality steel surgical scalpels: the cutting edge of the blade is only about three nanometers thick. All metal knives have a jagged, irregular blade when viewed under a strong enough microscope; however, obsidian blades are still smooth, even when examined under an electron microscope. One study found that obsidian incisions produced fewer inflammatory cells and less granulation tissue in a group of rats after seven days but the differences disappeared after twenty-one days. Don Crabtree has produced surgical obsidian blades and written articles on the subject. Obsidian scalpels may be purchased for surgical use on research animals. The major disadvantage of obsidian blades is their brittleness compared to those made of metal, thus limiting the surgical applications for obsidian blades to a variety of specialized uses where this is not a concern.
== Sources == This article incorporates text from a free content work. Licensed under CC BY 4.0 (license statement/permission). Text taken from The State of Agricultural Commodity Markets 2026, Food and Agriculture Organization of the United Nations. This article incorporates text from a free content work. Licensed under CC BY-SA 3.0 (license statement/permission). Text taken from The status of women in agrifood systems – Overview, FAO. This article incorporates text from a free content work. Licensed under CC BY-SA 3.0 (license statement/permission). Text taken from The State of Food and Agriculture 2021. Making agrifood systems more resilient to shocks and stresses, In brief, FAO. This article incorporates text from a free content work. Licensed under CC BY-SA 3.0 (license statement/permission). Text taken from Robust transport networks support agrifood systems' resilience, FAO, FAO. This article incorporates text from a free content work. Licensed under CC BY-SA 3.0 (license statement/permission). Text taken from Ensuring economic access to healthy diets during times of crisis, FAO, FAO. This article incorporates text from a free content work. Licensed under CC BY-SA 3.0 (license statement/permission). Text taken from International trade and the resilience of national agrifood systems, FAO, FAO. This article incorporates text from a free content work. Licensed under CC BY-SA 3.0 (license statement/permission). Text taken from The State of Food Security and Nutrition in the World 2021.
Alongside its priority for a reduction of global economic imbalances, France also identified support for Ukraine, protection of children, the fight against organised crime and illegal flows, and reform of global governance as major themes of the summit. G7 leaders adopted joint statements on mutually beneficial international partnerships, the Bundibugyo Ebola outbreak, cancer, geopolitical issues, migrant smuggling, drug trafficking, online safety for minors, balanced growth and critical mineral supply chains. In a statement on global imbalances, leaders called for stronger International Monetary Fund surveillance of external imbalances and asked the IMF and the OECD to monitor how domestic policy in major economies contributes to those imbalances. Egypt, Kenya and South Korea also supported the statement. The discussions included concerns over Chinese export practices, industrial overcapacity, subsidies and weak domestic consumption. The French foreign ministry described the 2026 summit as the first G7 leaders' summit to make cancer a priority, with objectives including support for research, data sharing and efforts to reduce cancer mortality. The health-related statements called for cooperation on cancer and announced more than $1 billion in funding for the response to the Bundibugyo Ebola outbreak, in line with United Nations efforts.
== Veterinary use == Hydrocodone is predominantly used as an antitussive in dogs. Hydrocodone has low oral bioavailability and provide poor analgesia in cats and dogs. One study in dogs found hydrocodone to be less effective than firocoxib for dogs undergoing a tibial-plateau-levelling osteotomy.
== External links == Cancer Research UK: An intelligent knife can tell ovarian cancer and healthy tissue apart. Could it make surgery smarter?[1] "Intelligent knife" tells surgeon if tissue is cancerous by Sam Wong Surgical Knife May Sniff Out Cancer By Tanya Lewis, Staff Writer | October 10, 2013 Heath, Nick, The Intelligent knife that helps surgeons sniff out cancer, European Technology, November 26, 2014, distributed in TechRepublic Daily Digest, TechRepublic.com, November 27, 2014 Jeevan, R; Cromwell, D. A; Trivella, M; Lawrence, G; Kearins, O; Pereira, J; Sheppard, C; Caddy, C. M; Van Der Meulen, J. H. P (2012). "Reoperation rates after breast conserving surgery for breast cancer among women in England: Retrospective study of hospital episode statistics". BMJ. 345 e4505. doi:10.1136/bmj.e4505. PMC 3395735. PMID 22791786. https://web.archive.org/web/20140322224442/http://www.doublexscience.org/iknife-excises-uncertainty-in-tumor-resection/
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.